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Consumption of simple carbohydrates has markedly increased over the past decades, and may be involved in the increased prevalence in metabolic
diseases. Whether an increased intake of fructose is specifically related to a dysregulation of glucose and lipid metabolism remains controversial.
We therefore compared the effects of hypercaloric diets enriched with fructose (HFrD) or glucose (HGlcD) in healthy men. Eleven subjects were
studied in a randomised order after 7 d of the following diets: (1) weight maintenance, control diet; (2) HFrD (3·5 g fructose/kg fat-free mass (ffm)
per d, þ35 % energy intake); (3) HGlcD (3·5 g glucose/kg ffm per d, þ35 % energy intake). Fasting hepatic glucose output (HGO) was measured
with 6,6-2H2-glucose. Intrahepatocellular lipids (IHCL) and intramyocellular lipids (IMCL) were measured by
1H magnetic resonance spec-
troscopy. Both fructose and glucose increased fasting VLDL-TAG (HFrD: þ59 %, P,0·05; HGlcD: þ31 %, P¼0·11) and IHCL (HFrD:
þ52 %, P,0·05; HGlcD: þ58 %, P¼0·06). HGO increased after both diets (HFrD: þ5 %, P,0·05; HGlcD: þ5 %, P¼0·05). No change was
observed in fasting glycaemia, insulin and alanine aminotransferase concentrations. IMCL increased significantly only after the HGlcD (HFrD:
þ24 %, NS; HGlcD: þ59 %, P,0·05). IHCL and VLDL-TAG were not different between hypercaloric HFrD and HGlcD, but were increased
compared to values observed with a weight maintenance diet. However, glucose led to a higher increase in IMCL than fructose.
Intrahepatic lipids: Intramyocellular lipids: VLDL-TAG: Hepatic insulin sensitivity
Consumption of refined sugars has markedly increased over
the past decades(1). In the Western world, these are mostly
consumed under two forms: either as sucrose, mainly
extracted from beet, and constituted of one molecule of fruc-
tose linked to one molecule of glucose; or as high-fructose
corn syrup, which consists in a mixture of free fructose and
glucose, the most common form being characterised by a fruc-
tose:glucose ratio of 55:45(2). Recently, the drastic increase in
high-fructose corn syrup consumption at the detriment of
sucrose has raised much concern(3). Several authors have
suggested that such increase in free fructose consumption
may be linked to the development of obesity and the metabolic
syndrome. Indeed, both in rodents and human subjects, high-
fructose diets (HFrD) lead to hypertriacylglycerolaemia,
insulin resistance and accumulation of ectopic lipid in the
liver and the muscle, known as intrahepatocellular lipids
(IHCL) and intramyocellular lipids (IMCL), respectively(4 – 6).
These deleterious effects were attributed to the fact that fruc-
tose, by bypassing the major regulatory point of glycolysis,
rapidly leads to an excess of triose phosphates in hepatocytes,
which may be used as substrates for de novo lipogenesis.
Several rodents(7,8) and human studies(9) have previously
shown that fructose was a more potent stimulator of lipo-
genesis than glucose. However, most of these studies were
performed in an acute setting, and it remains therefore
unknown whether chronic fructose-induced alterations of
lipid homoeostasis are due to specific fructose properties, or
are merely the result of energy and/or sugar overloading.
The aim of the present study was to compare the effects of
a hypercaloric 7-d HFrD v. high-glucose diet (HGlcD) on
ectopic lipids, glucose homoeostasis and plasma lipid profile.
Subjects and methods
Subjects
Eleven healthy non-smoking male volunteers (24·6 (SEM 0·6)
years; means with their standard errors) participated in the
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study. According to a physical examination and a brief medical
history, all subjects were in good health with a BMI between 19
and 25 kg/m2 and were moderately physically active (,1 h/
week). They were not taking any medications and did not regu-
larly consume alcohol or sugar-sweetened beverages.
Study design and diet
Each subject consumed, in a crossover randomised order, the
following diets: (1) a 7-d weight maintenance diet (total energy
intake equal to predicted basal energy requirement(10) £ 1·6),
containing 55 % carbohydrate (of which 11 % simple sugars),
30 % fat and 15 % protein; (2) the same weight maintenance
diet supplemented with 3·5 g fructose/kg fat-free mass per d:
HFrD; or (3) the weight maintenance diet supplemented with
3·5 g glucose/kg fat-free mass per d: HGlcD. Both HFrD
and HGlcD corresponded to an energy overload corresponding
to þ35 % energy requirements. The study was performed on an
outpatient basis, and during the 3 d preceding the metabolic
investigations, subjects were provided with all the dietary
constituents as pre-packed food items with instruction as to
how and when to consume them. Fructose and glucose were
administered as a 20 % solution with the three main meals. A
2–3-week washout period separated the three dietary conditions.
Leisure sport activity was restricted to ,1 h/week throughout
the study period. Compliance was assessed by interview.
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects/patients were approved by the ethical
board of Lausanne University School of Biology and Medicine.
Written informed consent was obtained from all subjects.
Metabolic investigation
Subjects reported at 07.00 hours to the metabolic unit of the
Lausanne University Hospital after a 10-h fast. Upon arrival,
subjects were asked to void, and body composition was esti-
mated from subcutaneous skinfold thickness measurements
at the biceps, triceps, subscapular and suprailiac sites(11). Par-
ticipants thereafter rested quietly in a bed in a semi-recumbent
position, and an indwelling catheter was inserted into the vein
of the right wrist for blood sampling. A second indwelling
catheter was inserted into an antecubital vein of the other
arm for infusion of 6,6-2H2 glucose. Fasting hepatic glucose
output was assessed in basal condition after a 2-h 6,6-2H2 glu-
cose infusion (bolus: 2 mg/kg; continuous: 20mg/kg per min)
by glucose isotope dilution analysis using Steele’s equations
for steady-state conditions(12). Blood was collected during
baseline for measurement of plasma concentrations of glucose,
lactate, insulin, non-esterified fatty acids, b-hydroxybutyric
acid, uric acid, total TAG, as well as VLDL, LDL and HDL
subfractions, alanine aminotransferase and leptin. Energy
expenditure and substrate utilisation were continuously
measured by indirect calorimetry (ventilated canopy) from
08.00 to 10.00 hours using the equations of Livesey & Elia(13).
Fasting hepatic insulin sensitivity index was calculated as(14):
Fasting hepatic insulin sensitivity index
¼ ð100=ðhepatic glucose output £ insulinÞÞ:
Analytical procedures
Plasma was immediately separated from blood by centrifugation
at 48C for 10 min at 3600 rpm and stored at2208C. Colorimetric
methods were used to assess plasma concentrations of NEFA
(kit from Wako Chemicals, Freiburg, Germany) and TAG
(kit from Biome´rieux Vitek, Inc., Durham, Switzerland).
Commercial RIA kits were used for the determination of
plasma insulin and leptin (LINCO Research, St Charles, MO,
USA). Subfractions of lipoproteins were separated by ultracen-
trifugation. b-Hydroxybutyric acid and lactate concentrations
were determined enzymatically using kits from Boehringer
(Mannheim, Germany). Plasma glucose concentration was
measured by the glucose oxidase method using a Beckman
glucose analyzer II (Beckman Instruments, Fullerton, CA,
USA). Plasma 6,6-2H2 glucose isotopic enrichment was
measured by GC–MS (Hewlett Packard Instruments, Palo
Alto, CA, USA), as previously described(15).
1H Magnetic resonance spectroscopy
All 1H-magnetic resonance spectroscopy examinations were
performed on a clinical 1·5 T MR scanner with data acquisition
(single-voxel localisation with 20 ms echo time) and processing
similar to a protocol described earlier for IMCL(16) and
IHCL(17). Fat content was expressed in mmol/kg.
Statistical analysis
Data are expressed as means with their standard errors. Stat-
istical analyses were performed with STATA version 8.2
and P,0·05 was considered statistically significant. Because
IHCL values were not normally distributed, they were
converted into log values before statistical analysis. All the
data were analysed by using repeated-measures ANOVA.
Post hoc comparisons were done by using the Student’s
paired t test.
Results
All subjects significantly gained weight after both hypercaloric
diets (Table 1). HFrD increased VLDL by 59 (SEM 24) % (range
228 to þ197), P,0·05 and IHCL by 52 (SEM 13) % (range
227 to þ203), P,0·05. With HGlcD, increases in similar
magnitudes were observed, but did not reach statistical signifi-
cance due to large interindividual variations in the response to
hypercaloric diets (VLDL-TAG: þ31 (SEM 20) % (range 244
to þ139), P¼0·11; IHCL: þ58 (SEM 23) % (range 229 to
þ226), P¼0·06 (Fig. 1). IHCL and VLDL-TAG were not
different with HFrD and HGlcD. No change was observed in
fasting glycaemia, insulin and alanine aminotransferase concen-
trations (Table 1). Both diets significantly decreased NEFA
and ketone bodies (Table 1). IMCL significantly increased
only after the HGlcD (fructose: þ49 (SEM 23) % (range 223
to þ239), NS; glucose: þ84 (SEM 86) % (range 220 to
þ319), P,0·05). Carbohydrate oxidation increased with a con-
comitant decrease in lipid oxidation after both hypercaloric
diets. Hepatic glucose output increased after both diets
(HFrD: þ5 %, P,0·05; HGlcD: þ5 %, P¼0·05; Table 1).
Hepatic insulin sensitivity index decreased to the same extent
after HFrD and HGlcD, but failed to reach significance.
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Discussion
It has been known for decades that a HFrD leads, in human
subjects or in rodents, to several features of the metabolic
syndrome, including hypertriacylglycerolaemia(16,18,19), insu-
lin resistance(20 – 22) and ectopic lipid deposition(21). However,
in several of these studies, high fructose intake was also
associated with a high energy intake, but was not compared
to a high glucose intake. This made it impossible to sort out
the effects of fructose per se and those of overfeeding with
simple sugars. In the present study, we show that a hyper-
caloric HGlcD leads to many of the metabolic alterations
associated with HFrD.
Few studies have directly compared the effects of fructose
v. glucose. When administered as part of a test meal, fructose
stimulates hepatic de novo lipogenesis to a greater extent than
glucose(9), and causes higher postprandial and 24-h triglycer-
idaemia(23,24). These differences observed after acute adminis-
tration are best explained by the distinct metabolism of these
two carbohydrates. Unlike glucose, fructose metabolism does
not require the action of insulin. After ingestion, fructose is
directly delivered in the liver, which constitutes the main
site of its metabolism. In hepatocytes, fructose is degraded
into triose phosphates, which can be diverted into one of the
following pathways: oxidation, lactate and glucose production
or de novo lipogenesis(25).
The chronic effects of a HFrD v. a HGlcD have been less
described. In a previous study, Bantle et al. (26) found that fruc-
tose, but not glucose, increased fasting and postprandial TAG in
healthy men. However, both sugars were consumed as part of an
isocaloric, weight maintenance diet. In obese human subjects,
overfeeding with fructose, but not with glucose, has been
reported to produce a slight increase in intra-visceral fat over
a 10-week period and to enhance postprandial plasma
TAG(27). In rodents, hypercaloric HFrD, but not HGlcD, led
to higher IHCL deposition and plasma TAG after 2 weeks(28).
Analysis of liver tissue revealed that both fructose and
glucose consumption stimulated lipogenic genes expression;
however, only fructose decreased hepatic expression and
activity of genes involved in lipid oxidation. It was therefore
suggested that fructose-induced inhibition of hepatic lipid
oxidation may be responsible for the IHCL accumulation(28).
The present results are at odds with some of these reports.
Fructose overfeeding indeed increased IHCL and VLDL-
TAG, as reported in rodents(28) and in human subjects(29).
The presently reported increase in IHCL was, however, of a
smaller magnitude than in our previous study(29), and
showed considerable inter-individual variability. Part of this
variability may be explained by genetic factors, since we
have reported that offsprings of patients with type 2 diabetes
have fructose-induced increases in IHCL(29). Inter-individual
differences in insulin sensitivity may also play a role since
hepatic insulin resistance has been shown to be strongly
associated with intrahepatic fat(30). However, and in contrast
with what was reported in rodents(28), we observed that glu-
cose overfeeding during 7 d also increased IHCL and plasma
VLDL-TAG. When expressed as the percentage change from
values observed with the control, weight maintenance diet,
fructose and glucose led to similar increases in IHCL and
Table 1. Anthropometric and metabolic parameters after the weight maintenance, the high-fructose (HFrD) and high-glucose diets
(HGlcD)
(Mean values with their standard errors)
Wt maintenance HFrD HGlcD
Mean SEM Mean SEM P* Mean SEM P†
Anthropometric parameters
Body wt (kg) 71·9 1·6 72·5 1·7 ,0·01 72·9 1·5 ,0·05
Body fat (%) 15 1 16 1 ,0·05 16 1 ,0·05
Metabolic parameters
Glucose (mg/l) 900 20 920 20 NS 900 20 NS
Lactate (mmol/l) 0·98 0·06 1·23 0·08 ,0·01 1·3 0·1 ,0·01
Insulin (pmol/l) 54·0 3·6 60·0 1·8 NS 58·2 3·6 NS
Non-esterified fatty acids (mmol/l) 560 40 354 23 ,0·01 330 36 ,0·01
b-Hydroxybutyrate (mmol/l) 0·07 0·01 0·02 0·01 ,0·01 0·01 0 ,0·01
Uric acid (mmol/l) 313 9 344 13 ,0·05 330 9 ,0·05
ALAT (U/l) 21 2 25 3 NS 26 4 NS
ASAT (U/l) 24 1 25 1 NS 25 2 NS
Indirect calorimetry
Energy expenditure (kJ/min) 4·14 0·04 4·18 0·04 NS 4·23 0·04 NS
Carbohydrates oxidation (mg/kg per min) 8·3 0·8 11·5 0·1 ,0·01 12·5 0·4 ,0·01
Lipid oxidation (mg/kg per min) 0·6 0·1 0·4 0·1 ,0·01 0·3 0·1 ,0·01
Hepatic metabolism
Hepatic insulin sensitivity index 5·5 0·3 4·5 0·1 0·06 4·7 0·3 NS
Fasting HGO (mg/kg per min) 2·2 0·1 2·3 0·1 ,0·05 2·3 0·1 0·05
Lipidic profile
Total TAG (mmol/l) 0·9 0·1 1·2 0·2 ,0·05 1·2 0·2 NS
HDL-cholesterol (mmol/l) 1·1 0·1 1·1 0·1 NS 1·1 0·1 NS
LDL-cholesterol (mmol/l) 2·4 0·1 2·2 0·1 NS 2·2 0·1 NS
Total cholesterol (mmol/l) 4 0·2 3·9 0·2 NS 3·8 0·2 NS
ALAT, Ala aminotransferase; ASAT, aspartate aminotransferase; HGO, hepatic glucose output.
* HFrD v. weight maintenance.
† HGlcD v. weight maintenance.
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plasma VLDL-TAG. However, interindividual variations were
more important with glucose than with fructose. Due to this
variability, the increases in IHCL and VLDL-TAG observed
after glucose fell short of reaching statistical significance.
This more inconstant increase in IHCL with glucose compared
to fructose may be possibly due to the fact that the pathways
used for hepatic lipid deposition may differ between these
two sugars. Fructose is essentially metabolised in liver cells,
and stimulation of hepatic de novo lipogenesis may be directly
linked to intrahepatic lipid storage and VLDL-TAG
secretion(22), while only part of the glucose administered is
metabolised in liver cells; hepatic lipid storage and dyslipidae-
mia during glucose overfeeding are therefore likely to rely
mainly on intrahepatic re-esterification of NEFA.
Both glucose and fructose overfeeding led to subtle, but sig-
nificant changes in fasting hepatic glucose metabolism, and
tended to decrease hepatic insulin sensitivity index. Although
the mechanisms responsible for this slight decrease in hepatic
insulin sensitivity remain unknown, it is tempting to speculate
that it is linked with intrahepatic fat deposition.
Unexpectedly, glucose overfeeding led to a substantial and
significant increase in IMCL deposition, while the increase
observed with fructose was of smaller magnitude and did
not reach statistical significance in this group of healthy sub-
jects. We have, however, reported previously that fructose
overfeeding also increases IMCL in healthy subjects and
in offsprings of patients with type 2 diabetes, and here
again, a considerable inter-individual variation is likely to be
responsible for failure to reach statistical significance in the
present study. The apparent larger increase in IMCL after
glucose may nonetheless reflect the different pathways used
for the metabolism of these two sugars. Contrarily to fructose,
a major portion of a glucose load is directly metabolised in
muscle, where it stimulates glucose oxidation(31). A concomi-
tant inhibition of muscle lipid oxidation may therefore favour
deposition of intramyocellular lipid.
Glucose and fructose overfeeding led to similar decreases
in plasma NEFA, indicating suppression of adipose tissue
lipolysis. This observation may appear surprising since insulin
is the major factor inhibiting lipolysis and glucose is expected
to produce much larger increase in insulin concentrations.
Adipocytes are, however, extremely sensitive to insulin, and
the slight increase in plasma insulin elicited by oral fructose
has been reported to be sufficient to significantly inhibit lipo-
lysis(32). Fructose overfeeding also suppressed basal, post-
absorptive NEFA, as previously reported(33). The mechanisms
remain hypothetical at this point, but may involve changes in
the expression of genes involved in lipid storage and/or lipid
oxidation.
In summary, our present data indicate that a short-term
overfeeding with either fructose or glucose leads within 7 d
to several potentially deleterious metabolic alterations in
healthy human subjects. Both sugars increased plasma TAG,
which may increase cardiovascular risk(34). Both sugars also
led to intrahepatic fat deposition, and such effect may, in
the long term, favour the development of non-alcoholic fatty
liver disease. They also led to slight alterations of hepatic
insulin sensitivity index. Finally, glucose overfeeding led to
a significant deposition of ectopic fat in muscle, which may,
in the long term, favour muscle insulin resistance(35). Both
diets were hypercaloric, and it is possible that excess energy
intake rather than specific effects of sugars was responsible
for these metabolic alterations. In support of this hypothesis,
we have recently reported that a short-term overfeeding with
30 % excess energy as saturated fat also increased IHCL con-
centrations(17). Fat overfeeding, however, failed to increase
plasma TAG concentrations, suggesting that sugars may
have additional effects on plasma lipid concentrations. From
a practical point of view, these results suggest that high
energy and high sugar intakes may confer a risk for the devel-
opment of metabolic disorders. In this perspective, reducing
sugar intake may be a primary target for prevention of meta-
bolic diseases.
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